 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Early Data Convinces Some Oncologists to Treat ROS1-Positive NSCLC Patients with Xalkori
June 06, 2012
Early Data Convinces Some Oncologists to Treat ROS1-Positive NSCLC Patients with Xalkori
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA OK for Pfizer's Xalkori and Companion Dx Highlights Upside for PGx Strategies in Drug Development
September 7, 2011 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Pfizer and Collaborators Developing Next-Gen Sequencing Test for Crizotinib Resistance Mutations
March 27, 2013 / Pharmacogenomics Reporter - Abbott Challenges 'Incorrect Assumptions' in Cost-Effectiveness Study of Xalkori PGx Testing
March 28, 2012 / Pharmacogenomics Reporter - Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders
March 21, 2012 / Pharmacogenomics Reporter